Eiko Lifesciences Ltd

Eiko Lifesciences Ltd., a speciality chemicals manufacturer, reported a consolidated net profit of ₹1.30 crores for Q4 FY26, marking a modest sequential increase of 7.44% from ₹1.21 crores in Q3 FY26, though significantly ahead of the ₹1.05 crores posted in Q4 FY25—a year-on-year gain of 23.81%. The micro-cap company, with a market capitalisation of ₹73.00 crores, saw its stock surge 7.39% on May 26 to close at ₹53.03, as investors responded positively to the topline momentum despite lingering concerns about profitability metrics and weak return ratios.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 May 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 May 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

A 30.3% decline from its 52-week high of Rs 65.9 has dragged Eiko Lifesciences Ltd to a fresh 52-week low of Rs 45.9 on 30 Mar 2026, marking a notable downturn despite recent positive earnings trends.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 March 2026, providing investors with the most up-to-date insight into the company's performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Eiko Lifesciences Ltd is rated Sell by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 16 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Eiko Lifesciences Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 20 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 03 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Eiko Lifesciences Ltd, a player in the Specialty Chemicals sector, has witnessed a notable improvement in its valuation attractiveness, shifting from very attractive to attractive. Despite a mixed performance against benchmark indices, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a more compelling entry point for investors, even as its overall market sentiment remains cautious with a recent downgrade to a Sell rating.

Eiko Lifesciences Ltd., a micro-cap speciality chemicals manufacturer, reported consolidated net profit of ₹1.08 crores for Q2 FY26, marking an impressive 285.71% year-on-year surge from ₹0.28 crores in Q2 FY25. However, despite the strong earnings momentum, the stock continues to languish, trading at ₹51.01 with a market capitalisation of just ₹71.00 crores, reflecting persistent investor scepticism about the company's long-term sustainability.